Brokerages Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Target Price at $4.25

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have been assigned an average recommendation of “Hold” from the seven research firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $4.25.

A number of brokerages have recently issued reports on INO. Weiss Ratings cut Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, July 1st. HC Wainwright lowered their target price on Inovio Pharmaceuticals from $3.00 to $2.50 and set a “neutral” rating on the stock in a research note on Monday, June 1st. Finally, Wall Street Zen cut Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, June 21st.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Eversept Partners LP acquired a new stake in Inovio Pharmaceuticals during the first quarter worth approximately $1,802,000. Renaissance Technologies LLC raised its holdings in Inovio Pharmaceuticals by 16.4% in the 1st quarter. Renaissance Technologies LLC now owns 643,777 shares of the biopharmaceutical company’s stock valued at $1,120,000 after acquiring an additional 90,613 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in Inovio Pharmaceuticals by 1,929.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 48,948 shares of the biopharmaceutical company’s stock valued at $85,000 after acquiring an additional 46,536 shares in the last quarter. Virtu Financial LLC bought a new stake in shares of Inovio Pharmaceuticals during the 4th quarter valued at $77,000. Finally, Janus Henderson Group PLC grew its holdings in shares of Inovio Pharmaceuticals by 1.3% during the 4th quarter. Janus Henderson Group PLC now owns 3,308,406 shares of the biopharmaceutical company’s stock worth $5,773,000 after purchasing an additional 42,146 shares in the last quarter. 26.79% of the stock is currently owned by institutional investors and hedge funds.

Inovio Pharmaceuticals Stock Performance

NASDAQ INO opened at $1.02 on Friday. The stock has a market cap of $83.92 million, a PE ratio of -0.70 and a beta of 1.48. The firm has a 50-day moving average of $1.17 and a 200-day moving average of $1.38. Inovio Pharmaceuticals has a 52-week low of $1.00 and a 52-week high of $2.98.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.02. As a group, analysts predict that Inovio Pharmaceuticals will post -1.03 EPS for the current fiscal year.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.